BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 10, 2023
Product Development

NorthSea pivots to diabetic NASH patients on Phase IIb icosabutate data

Misses primary non-alcoholic steatohepatitis resolution endpoint in all comers, but hits in Type II diabetes subgroup
BioCentury | Aug 10, 2023
Product Development

Obesity mechanisms in the clinic: which overlap, and which branch out

Like incretins, most clinical programs modulate glucose homeostasis and appetite, but a few work in new ways that could be more selective for fat loss
BioCentury | Mar 29, 2023
Product Development

Next up in obesity therapeutics

Late-stage pipeline dominated by large pharmas, GLP-1 combinations 
BioCentury | Oct 25, 2018
Distillery Therapeutics

Neurology

BioCentury | Sep 14, 2017
Strategy

Numerate’s Intelligence

How Numerate’s AI tackles translational questions with tiny data sets
BioCentury | Feb 2, 2017
Distillery Therapeutics

Endocrine / Metabolic

BioCentury | Dec 4, 2014
Cover Story

GPCRs' grand plans

BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

Takeda needs to execute on cost-cutting, pipeline to meet EPS expectations
BioCentury | Aug 14, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Items per page:
1 - 10 of 29
Help Center
Username
Request Training
Submit Data Correction
Ask a Question